Therapy Areas: Inflammatory Diseases
UCB launches scholarship program for adults living with hidradenitis suppurativa
2 June 2026 - Biopharmaceutical company UCB (EBR:UCB) announced on Monday the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship Program.This program is designed to support adults age 18...
Upsher-Smith launches generic Cyclosporine Ophthalmic Emulsion 0.05%
21 May 2026 - Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472 and OTCQX:BORAY), announced on Wednesday that it has launched its Cyclosporine Ophthalmic Emulsion 0.0...
Accro Bioscience completes USD50m Series C financing
19 May 2026 - Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.The round was led by OrbiMed, with participation from TCG Cross...
Atisama Therapeutics reports progress in Phase 1 study of RB042
18 May 2026 - Atisama Therapeutics (formerly Rage Bio), an Australian clinical-stage biotechnology company, on Friday reported progress in the Phase 1 study of its lead candidate, RB042.The RB042 Phas...
Mabwell's clinical trial application for 9MW5211 cleared by US FDA
11 May 2026 - Chinese biopharmaceutical company Mabwell (SH:688062) (HK:02493) announced on Friday that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel an...
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
4 May 2026 - Australia-based independent biopharmaceutical company Specialised Therapeutics (ST) announced on Sunday that its NIKTIMVO (axatilimab) has been approved for use in Australia by the Therap...